SERENTIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Serentil, and when can generic versions of Serentil launch?
Serentil is a drug marketed by Novartis and is included in three NDAs.
The generic ingredient in SERENTIL is mesoridazine besylate. There are two drug master file entries for this compound. Additional details are available on the mesoridazine besylate profile page.
Summary for SERENTIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Patent Applications: | 3,975 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | SERENTIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SERENTIL
US Patents and Regulatory Information for SERENTIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SERENTIL | mesoridazine besylate | CONCENTRATE;ORAL | 016997-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | SERENTIL | mesoridazine besylate | TABLET;ORAL | 016774-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | SERENTIL | mesoridazine besylate | INJECTABLE;INJECTION | 016775-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
